Curiox BioSystems
Financials
Valuation Metrics
Curiox BioSystems's Market Cap is ₩7854B. At end of 2025 it was ₩2.0T. Ranked #345 of 2,421 in KR market (top 14%), #103 of 1,640 on KOSDAQ (top 6%), #38 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 16%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 785.45B KRW | KR#345/2,421 Sec#38/231 |
| Revenue | 5.73B KRW | KR#2,330/2,421 Sec#189/231 |
| Net Income | -12.78B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 53.33B KRW | KR#2,182/2,421 Sec#196/231 |
| Net Assets | 48.99B KRW | KR#1,918/2,421 Sec#160/231 |
| Employees | 23 | KR#2,239/2,421 Sec#210/231 |
| Value | ||
| P/B | 16.03x | KR#2,396/2,421 Sec#220/231 |
| P/S | 136.97x | KR#2,398/2,421 Sec#215/231 |
| FCF Yield | -1.43% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -26.09% | KR#2,148/2,421 Sec#168/231 |
| ROA | -23.96% | KR#2,273/2,421 Sec#185/231 |
| Op. Margin | -227.43% | KR#2,339/2,421 Sec#186/231 |
| Revenue Growth | 49.92% | KR#209/2,421 Sec#29/231 |
| Financial Health | ||
| Debt Ratio | 8.87% | KR#118/2,421 Sec#25/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | -11.25B KRW | KR#1,744/2,421 Sec#155/231 |
| Cash | 10.50B KRW | KR#1,666/2,421 Sec#141/231 |
| Current Ratio | 5.24x | KR#268/2,421 Sec#49/231 |
| Performance | ||
| 1Y Return | -19.86% | KR#1,257/2,421 Sec#85/231 |
| 1M Return | 5.19% | KR#744/2,421 Sec#54/231 |
| From 52W High | -69.44% | KR#2,180/2,421 Sec#188/231 |
| 1Y MDD | -75.43% | KR#2,192/2,421 Sec#193/231 |
| Trading | ||
| Volume | 83,817 shares | KR#868/2,421 Sec#85/231 |
| Trading Value | 3.87B KRW | KR#418/2,421 Sec#42/231 |
| Foreign Own. | 7.03% | KR#636/2,421 Sec#56/231 |
| Per Share | ||
| EPS | -742 KRW | KR—/2,421 Sec—/231 |
| BPS | 2,844 KRW | KR#1,893/2,421 Sec#144/231 |
Company Info
Curiox Biosystems was established in 2018 to commercialize cell analysis process automation technology, developing a global sales network via subsidiaries in the United States, China, and Singapore. The company sells automated cell pre-processing equipment, plates, and accessories, featuring its unique Curiox C-FREE™ technology that significantly improves automation, data accuracy, and reproducibility in cell analysis. This non-centrifuge-based automated cell pre-processing product grants it a distinctive market position. Curiox Biosystems is headquartered in Geumcheon-gu, Seoul Metropolitan City.